Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2012

View Archived Issues

Novel TTK inhibitors patented by Bayer Schering Pharma

Array BioPharma synthesizes novel kinase inhibitors

Allergan patents new CCR2 receptor antagonists

Novel protein kinase inhibitors disclosed by Roche

German researchers present new GPR119 receptor agonists

Abbott designs new potential hepatitis therapies

AbOs-targeted antibodies show potential in Alzheimer's disease model

Abbott halts development of two clinical-stage candidate drugs for Alzheimer's disease

New AHA/ACC guideline update includes ticagrelor

New candidate biomarker for prostate cancer discovered

Eisai and Verastem enter research collaboration

AstraZeneca plans to evaluate ticagrelor in patients with PAD

Oncolytic virus research collaboration begins for bladder cancer

Phase II results presented on insulin analogue for diabetes

German authorities approve SkyePharma's asthma product

FDA advisory committee to discuss NDAs for Novo Nordisk insulin products

FDA approves VIVUS drug for weight management

U.S. scientists develop new model of early-onset Alzheimer's disease

Orphan medicinal product designation granted for levoglutamide

Janssen seeks U.S. and E.U. approval for Simponi

Grifols to conduct safety study of inhaled alpha1-proteinase inhibitor

Medgenics commences Israeli study of Epodure Biopumps

Isotechnika receives further funding from Canadian government

Nymox provides update on pivotal U.S. phase III trials in BPH

Antisense Therapeutics executes agreement for ATL-1102

FDA grants orphan drug status to antibody-drug conjugate in mesothelioma

Soligenix receives grant for acute radiation syndrome therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...